Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus BRIELLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus BRIELLYN.
BALZIVA-28 vs BRIELLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Category C
Category C
Oral Contraceptive
Oral Contraceptive